menu
    • menu
    [{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Mass General Brigham Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Mass General Brigham Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Mass General Brigham Ventures"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.16,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Redmile Group"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Series C Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ RA Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ RA Capital Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Abcuro, Inc

    Menu

    Abcuro, Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : RA Capital Management

                            Deal Size : $200.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug

                            Details : The Proceeds will used to support the completion of the registrational Phase 2/3 MUSCLE trial of ABC008 (ulviprubart) in inclusion body myositis, BLA filing, and commercial launch preparation.

                            Product Name : ABC008

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 12, 2025

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : RA Capital Management

                            Deal Size : $200.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Redmile Group

                            Deal Size : $155.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline

                            Details : Abcuro will use the proceeds from the financing to complete a Phase 2/3 registrational clinical trial evaluating ABC008, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of inclusion body myosi...

                            Product Name : ABC008

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            August 17, 2023

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Redmile Group

                            Deal Size : $155.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Bod...

                            Details : ABC008 is a first-in-class anti-KLRG1 antibody, designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM), T cell large granular lymphocytic leukemia (T-LGLL), and mature T cell...

                            Product Name : ABC008

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 31, 2023

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

                            Details : ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells.

                            Product Name : ABC008

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 04, 2023

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia

                            Details : ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells.

                            Product Name : ABC008

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 10, 2022

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Mass General Brigham Ventures

                            Deal Size : $42.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Abcuro Raises $42 Million in Series A-1 Financing

                            Details : Proceeds from this financing will be used to advance ABC008, an anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy tissue in a variety of autoimmune diseases.

                            Product Name : ABC008

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 01, 2021

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Mass General Brigham Ventures

                            Deal Size : $42.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Deplet...

                            Details : ABC008 is an anti-KLRG1 antibody capable of selectively depleting subpopulations of highly cytotoxic, tissue-damaging, late-differentiated effector memory (TEM) and effector (TEMRA) T cells for treatment of inclusion body myositis (IBM), an autoimmune di...

                            Product Name : ABC008

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 10, 2021

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Abcuro, Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclus...

                            Details : Preliminary data also show potential improvement in disease severity of IBM in the first cohort and evidence of a dose response in the second cohort with ABC008 0.5 mg/kg for depletion of highly cytotoxic T cells.

                            Product Name : ABC008

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 11, 2021

                            Lead Product(s) : Ulviprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth